Loxo Oncology (NASDAQ:LOXO) had its price target hoisted by equities research analysts at Citigroup to $178.00 in a report released on Friday, The Fly reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup’s price target would suggest a potential upside of 6.25% from the company’s current price.

Other equities analysts have also issued reports about the company. BidaskClub raised Loxo Oncology from a “hold” rating to a “buy” rating in a report on Tuesday, January 23rd. Stifel Nicolaus reaffirmed a “buy” rating and issued a $135.00 target price on shares of Loxo Oncology in a report on Friday, March 2nd. Cann reaffirmed a “buy” rating and issued a $122.00 target price on shares of Loxo Oncology in a report on Thursday, March 1st. Zacks Investment Research raised Loxo Oncology from a “hold” rating to a “buy” rating and set a $148.00 target price for the company in a report on Friday, March 9th. Finally, William Blair reiterated a “buy” rating on shares of Loxo Oncology in a research note on Monday, April 16th. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and three have given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $155.89.

Loxo Oncology opened at $167.53 on Friday, Marketbeat.com reports. The company has a market capitalization of $4.20 billion, a PE ratio of -31.55 and a beta of 2.32. Loxo Oncology has a 12-month low of $138.92 and a 12-month high of $143.55.

Loxo Oncology (NASDAQ:LOXO) last released its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.01. During the same period in the prior year, the business earned ($0.96) earnings per share. analysts anticipate that Loxo Oncology will post 0.6 EPS for the current year.

In other Loxo Oncology news, VP Jennifer Burstein sold 1,700 shares of the stock in a transaction on Tuesday, March 13th. The stock was sold at an average price of $131.33, for a total transaction of $223,261.00. Following the sale, the vice president now owns 1,700 shares in the company, valued at $223,261. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Joshua H. Bilenker sold 15,000 shares of the stock in a transaction on Wednesday, April 25th. The stock was sold at an average price of $131.12, for a total value of $1,966,800.00. Following the sale, the chief executive officer now owns 190,207 shares in the company, valued at approximately $24,939,941.84. The disclosure for this sale can be found here. In the last quarter, insiders sold 62,646 shares of company stock worth $8,331,001. 44.40% of the stock is owned by company insiders.

Several large investors have recently bought and sold shares of the business. New York State Common Retirement Fund lifted its position in shares of Loxo Oncology by 1.6% during the first quarter. New York State Common Retirement Fund now owns 24,700 shares of the biopharmaceutical company’s stock worth $2,850,000 after acquiring an additional 400 shares in the last quarter. Teachers Advisors LLC lifted its position in shares of Loxo Oncology by 1.3% during the fourth quarter. Teachers Advisors LLC now owns 41,592 shares of the biopharmaceutical company’s stock worth $3,501,000 after acquiring an additional 541 shares in the last quarter. Cambridge Investment Research Advisors Inc. lifted its position in shares of Loxo Oncology by 26.8% during the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 2,917 shares of the biopharmaceutical company’s stock worth $246,000 after acquiring an additional 617 shares in the last quarter. Swiss National Bank lifted its position in shares of Loxo Oncology by 2.0% during the first quarter. Swiss National Bank now owns 36,400 shares of the biopharmaceutical company’s stock worth $4,199,000 after acquiring an additional 700 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System lifted its position in shares of Loxo Oncology by 7.3% during the first quarter. State Board of Administration of Florida Retirement System now owns 11,859 shares of the biopharmaceutical company’s stock worth $1,368,000 after acquiring an additional 809 shares in the last quarter.

About Loxo Oncology

Loxo Oncology, Inc, a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer.

The Fly

Analyst Recommendations for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.